AM Best said the reinsurer showed a strong balance sheet after 2 capital injections.
FuSure Reinsurance Company Limited expects to sustain double-digit premium growth through 2028, supported by a stronger capital position and continued backing from parent company Tencent Holdings.
AM Best FuSure has shown a strong balance sheet following two rounds of capital injections from shareholders, as well as expectations of additional capital support in the medium term.
FuSure projects double-digit annual net premium written growth between 2026 and 2028, whilst maintaining a mid-single-digit return on equity (ROE).
In 2025, the reinsurer posted an ROE of 5.2%, according to AM Best.
Since launching in 2021, FuSure has focused on health reinsurance in Greater China, whilst gradually expanding into long-term health reinsurance and commercial property business across the Asia-Pacific region.
The company has also broadened its business mix by product line, geography, distribution channels and client base.
AM Best said FuSure’s capital position remains a key strength.
The reinsurer received an additional HK$1bn capital injection in 2025, bringing its total capital and surplus to HK$3.15bn at the end of the year, exceeding its initial five-year capital plan.